Legend Biotech earned FIT’s Newcomer of the Year award (Foreign Investment Trophy)
Flanders Investment and Trade is a Flemish government organization that facilitates investment projects in Flanders, a northern region of Belgium, and supports Flemish companies. The Foreign Investment Trophy recognizes international firms with investment projects in Flanders, and FIT’s Newcomer of the Year award is conferred upon organizations who have recently embarked on substantial investment projects in the region.
Legend Biotech earned the honor for its joint investment in a state-of-the-art manufacturing facility in Flanders with Janssen Pharmaceutica N.V. (Janssen). The cell therapy facility is the first-ever cell therapy manufacturing site located in Flanders, and it will serve as a regional hub for the companies’ cell therapy production for patients in Europe, the Middle East and Africa.
The 26,000-square-meter manufacturing hub is part of Legend’s collaboration with Janssen to advance the manufacturing of ciltacabtagene autoleucel (cilta-cel), a B cell maturation antigen-directed CAR-T treatment being evaluated for the treatment of relapsed or refractory multiple myeloma by the European Medicines Agency.
The European manufacturing hub is anticipated to come on-line in 2023 and will be managed by Legend Biotech. As he accepted the award in Belgium, Ying Huang, PhD, CEO and CFO of Legend Biotech, said: “This award is special recognition of our investment in Flanders, one of Europe’s most exciting biotechnology hubs. The Newcomer of the Year award marks how far we’ve come in since Legend was established to apply cell therapy to rare and uncommon diseases. We look forward to advancing that goal and to playing a meaningful role in the Ghent ecosystem for years to come.”
About Legend Biotech Legend Biotech is a global biotechnology company dedicated to treating, and one day curing, life threatening diseases. Headquartered in Somerset, New Jersey, we are developing advanced cell therapies across a diverse array of technology platforms, including autologous and allogenic chimeric antigen receptor T natural killer (NK) cell– cell, Tcell receptor (TCRT), and based immunotherapy.